383 related articles for article (PubMed ID: 25636340)
1. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
2. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
3. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
8. Impact of acquired del(17p) in multiple myeloma.
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
[TBL] [Abstract][Full Text] [Related]
9. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
10. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau H; Attal M; Moreau P; Charbonnel C; Garban F; Hulin C; Leyvraz S; Michallet M; Yakoub-Agha I; Garderet L; Marit G; Michaux L; Voillat L; Renaud M; Grosbois B; Guillerm G; Benboubker L; Monconduit M; Thieblemont C; Casassus P; Caillot D; Stoppa AM; Sotto JJ; Wetterwald M; Dumontet C; Fuzibet JG; Azais I; Dorvaux V; Zandecki M; Bataille R; Minvielle S; Harousseau JL; Facon T; Mathiot C
Blood; 2007 Apr; 109(8):3489-95. PubMed ID: 17209057
[TBL] [Abstract][Full Text] [Related]
11. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
[TBL] [Abstract][Full Text] [Related]
12. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
[TBL] [Abstract][Full Text] [Related]
14. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Chretien ML; Corre J; Lauwers-Cances V; Magrangeas F; Cleynen A; Yon E; Hulin C; Leleu X; Orsini-Piocelle F; Blade JS; Sohn C; Karlin L; Delbrel X; Hebraud B; Roussel M; Marit G; Garderet L; Mohty M; Rodon P; Voillat L; Royer B; Jaccard A; Belhadj K; Fontan J; Caillot D; Stoppa AM; Attal M; Facon T; Moreau P; Minvielle S; Avet-Loiseau H
Blood; 2015 Dec; 126(25):2713-9. PubMed ID: 26516228
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting.
Garrido D; Slavutsky I; Riva E;
Curr Probl Cancer; 2023 Feb; 47(1):100916. PubMed ID: 36473780
[TBL] [Abstract][Full Text] [Related]
16. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.
Avet-Loiseau H; Hulin C; Campion L; Rodon P; Marit G; Attal M; Royer B; Dib M; Voillat L; Bouscary D; Caillot D; Wetterwald M; Pegourie B; Lepeu G; Corront B; Karlin L; Stoppa AM; Fuzibet JG; Delbrel X; Guilhot F; Kolb B; Decaux O; Lamy T; Garderet L; Allangba O; Lifermann F; Anglaret B; Moreau P; Harousseau JL; Facon T
J Clin Oncol; 2013 Aug; 31(22):2806-9. PubMed ID: 23796999
[TBL] [Abstract][Full Text] [Related]
18. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
20. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
